BofA lowered the firm’s price target on ResMed (RMD) to $280 from $290 and keeps a Buy rating on the shares. The firm updated its model for tariffs while also flagging that tariffs could lead to rising U.S. inflation and a weaker U.S. dollar though it has not made changes to estimates for inflation and foreign exchange given underlying uncertainty. The firm estimate yesterday’s tariff announcement will have a negative 6% impact on ResMed’s FY26 EPS.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- Resmed’s Resilience and Growth Prospects Amid Tariff Challenges: A Buy Recommendation
- Morgan Stanley Sees Near-Term Rally Ahead — Here Are 2 Stocks to Bet on It
- ResMed initiated with an Overweight at Morgan Stanley
- ResMed announces publication of data on CPAP therapy
- ResMed announces brand evolution designed to unify portfolio